Cardiovascular outcomes of enzyme‐inducing anti‐seizure medications: A real‐world Asian cohort study
Epileptic Disorders · 2026-09-30
DOI: 10.1002/epd2.70430 ↗Abstract
Abstract Objective To determine whether enzyme‐inducing anti‐seizure medications (EIASMs) are associated with differential risks of major adverse cardiovascular events (MACE) and all‐cause mortality compared with non‐enzyme‐inducing anti‐seizure medications (NEIASMs) in adults with epilepsy. Methods Using the Chang Gung Research Database (2010–2019), adults with epilepsy receiving at least 28 cumulative days of anti‐seizure medication therapy within 180 days of the index date were classified as EIASMs or NEIASMs users. Stabilized inverse probability of treatment weighting (IPTW) addressed confounding by indication. Composite MACE encompassing myocardial infarction (MI), arrhythmia, heart failure, ischemic stroke, hemorrhagic stroke, and sudden cardiac death and all‐cause mortality were co‐primary endpoints evaluated using Cox proportional hazards and Fine–Gray competing risk models. Results Of 20 693 eligible patients, 10 571 received EIASMs and 10 122 received NEIASMs. After IPTW, all covariates were balanced (absolute standardized mean differences
EUVIMED